### **ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES**

## VACCINES FOR CHILDREN PROGRAM

## VACCINES TO PREVENT MPOX

The purpose of this resolution is to add a vaccine for the prevention of mpox to the Vaccines for Children Program.

# **Eligible Groups**

- Children aged 18 years of age at increased risk of mpox, including:
  - Persons who are gay, bisexual and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had:
    - At least 1 sexually transmitted disease
    - More than 1 sex partner
    - Sex at a commercial sex venue
    - Sex in association with a large public event in a geographic area where mpox transmission is occurring
  - Persons who are sexual contacts of the persons described above
  - o Persons who anticipate experiencing any of the situations described above

### **Recommended Vaccination Schedule and Intervals**

• Two doses, 28 days apart

### **Recommended dosage**

Refer to product package inserts

### **Contraindications and Precautions**

#### Contraindications

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component as listed in the package insert <u>Package-Insert-JYNNEOS (fda.gov)</u>.

#### Precautions

- Simultaneous administration of mpox vaccine with COVID-19 vaccine (due to a hypothetical increased risk for myocarditis/pericarditis following vaccination)
- Moderate or severe acute illness, with or without fever

[If an ACIP recommendation or notice regarding meningococcal vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: October 25, 2023

This document can be found on the CDC website at: https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html